News Wire

François de Brantes, whose payment reform organization merged with the Altarum institute about a year ago, has been fired. His last day was Friday. An email from Altarum’s president and CEO, Lincoln Smith, that circulated at the institute, said he had “tremendous respect” for de Brantes but after…
An analysis commissioned by a pharmaceutical industry trade group found that hospitals participating in the 340B Drug Discount Program have higher per-patient outpatient pharmacy costs than their non-340B counterparts––indicating patients at 340B hospitals are prescribed more medicines, more expensive…
A pregnant woman who becomes ill from the Zika virus faces a 7% chance that her child will be born with birth defects, and that risk jumps to nearly 13% if she becomes ill during the first trimester, a study conducted in French territories in the Americas has concluded. The finding “emphasizes the…
A new treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) that would cut the number of infusions needed each year by three-quarters fared well in a pivotal phase 3 study, the developer announced.  ALXN1210 (Alexion Pharmaceuticals, Inc.), an investigational long-acting C5…
Smoking is associated with increased risk of hearing loss, according to a study of more than 50,000 participants over eight years. Researchers analyzed data from annual health checkups, which included audio testing performed by a technician and a health-related lifestyle questionnaire completed by each…
The FDA has granted a breakthrough therapy designation for erdafitinib (Janssen Pharmaceuticals) in the treatment of urothelial cancer, an often-aggressive disease with a grim prognosis that is seen most frequently in the bladder. It’s the sixth most common type of cancer in the U.S. The breakthrough…
Urgent action must be taken to address the dramatic rise of cancer drug prices and to better align prices with value, according to a report released by the President's Cancer Panel. The panel's report, Promoting Value, Affordability, and Innovation in Cancer Drug Treatment, found that while some cancer…
African-American men lowered their high blood pressure to healthy levels when aided by a pharmacist and their barber, according to a study from the Smidt Heart Institute. The findings were published in the New England Journal of Medicine and presented as a late-breaking clinical trial at the American…
GlaxoSmithKline (GSK) has won a further reprieve for its blockbuster lung drug Advair (fluticasone propionate and salmeterol inhalation powder) after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug, Reuters reports. The Jordan-based…
Generic antiplatelet drugs seem to work as well as a brand-name drug for heart patients, according to research published in Circulation: Cardiovascular Quality and Outcomes. When a Canadian health system switched from prescribing brand-name Plavix (clopidogrel bisulfate, Bristol-Myers Squibb/Sanofi)…
A large study of cardiovascular events in gout patients taking one of two medications to prevent excess build-up of uric acid has found that one of the drugs, febuxostat (Uloric, Takeda), increased the risk of death for those with heart disease compared with the other drug, allopurinol. Yet the two…
Alirocumab injection (Praluent, Regeneron Pharmaceuticals/Sanofi) reduced the risk of major cardiac events by 15% among patients who had suffered heart attacks and other coronary events in the ODYSSEY OUTCOMES trial. The two companies have announced that they are willing to offer price breaks on the…
Disappointing results in the phase 3 RESULT trial have led Anthera Pharmaceuticals, Inc., to discontinue development of its drug candidate Sollpura for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis. Sollpura failed to meet the trial’s primary endpoint: noninferiority in…
Canagliflozin (Invokana, Janssen Pharmaceutical) significantly reduced the risk of cardiovascular death or hospitalization for heart failure in patients with type-2 diabetes at high cardiovascular risk in an exploratory analysis from the CANVAS clinical program, according to a presentation at the American…
The FDA has  issued warning letters to all three duodenoscope manufacturers for failing to comply with requirements of federal law under which they were ordered to conduct postmarket surveillance studies to assess the effectiveness of reprocessing the devices. As part of an ongoing effort to prevent…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA